Catalent takes on manufacture of J&J’s coronavirus vaccine
Catalent announces partnership with J&J to manufacture lead COVID-19 vaccine candidate, plans to hire 300 staff and manufacture 24/7.
Catalent announces partnership with J&J to manufacture lead COVID-19 vaccine candidate, plans to hire 300 staff and manufacture 24/7.
Under the agreement, AZ will develop, manufacture and distribute the vaccine that has already begun Phase I trials.